Lifestyle treatments in cystic fibrosis: The NHS should pay

With the NHS under increasing financial pressure and healthcare costs soaring year on year, it is perhaps not surprising that assessment agencies focus on cost-effectiveness analysis when assessing new therapies. Such an approach does not however, always take sufficient account of treatment burden, lifestyle and patient choice and therefore new equally effective but perhaps “easier to take” formulations and faster delivery systems for current therapies do not always take precedence in current treatment guidelines.
Source: Paediatric Respiratory Reviews - Category: Respiratory Medicine Authors: Source Type: research